Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Syneos Health stock
Own Syneos Health stock in just a few minutes.
Fact checked
Syneos Health, Inc is a diagnostics & research business based in the US. Syneos Health shares (SYNH) are listed on the NASDAQ and all prices are listed in US Dollars. Syneos Health employs 24,310 staff and has a trailing 12-month revenue of around USD$4.4 billion.
How to buy shares in Syneos Health
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Syneos Health. Find the stock by name or ticker symbol: SYNH. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Syneos Health reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Syneos Health, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Syneos Health. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Syneos Health share price
Use our graph to track the performance of SYNH stocks over time.Syneos Health shares at a glance
Information last updated 2021-03-03.
| 52-week range | USD$30.02 - USD$81.35 |
|---|---|
| 50-day moving average | USD$76.4497 |
| 200-day moving average | USD$65.1702 |
| Wall St. target price | USD$85.6 |
| PE ratio | 41.2568 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$1.83 |
Buy Syneos Health shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Syneos Health stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Syneos Health under- or over-valued?
Valuing Syneos Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Syneos Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Syneos Health's P/E ratio
Syneos Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Syneos Health shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Syneos Health's PEG ratio
Syneos Health's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.791. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Syneos Health's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Syneos Health's EBITDA
Syneos Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$575.2 million.
The EBITDA is a measure of a Syneos Health's overall financial performance and is widely used to measure a its profitability.
Syneos Health financials
| Revenue TTM | USD$4.4 billion |
|---|---|
| Operating margin TTM | 7.99% |
| Gross profit TTM | USD$1 billion |
| Return on assets TTM | 2.84% |
| Return on equity TTM | 6.15% |
| Profit margin | 4.37% |
| Book value | $31.194 |
| Market capitalisation | USD$7.9 billion |
TTM: trailing 12 months
Shorting Syneos Health shares
There are currently 4.5 million Syneos Health shares held short by investors – that's known as Syneos Health's "short interest". This figure is 6.8% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting Syneos Health shares can be evaluated.
Syneos Health's "short interest ratio" (SIR)
Syneos Health's "short interest ratio" (SIR) is the quantity of Syneos Health shares currently shorted divided by the average quantity of Syneos Health shares traded daily (recently around 646042.56854257). Syneos Health's SIR currently stands at 6.93. In other words for every 100,000 Syneos Health shares traded daily on the market, roughly 6930 shares are currently held short.
However Syneos Health's short interest can also be evaluated against the total number of Syneos Health shares, or, against the total number of tradable Syneos Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syneos Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Syneos Health shares in existence, roughly 40 shares are currently held short) or 0.0717% of the tradable shares (for every 100,000 tradable Syneos Health shares, roughly 72 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syneos Health.
Find out more about how you can short Syneos Health stock.
Syneos Health share dividends
We're not expecting Syneos Health to pay a dividend over the next 12 months.
Syneos Health share price volatility
Over the last 12 months, Syneos Health's shares have ranged in value from as little as $30.02 up to $81.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syneos Health's is 1.8074. This would suggest that Syneos Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syneos Health overview
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Frequently asked questions
More guides on Finder
-
How to buy Achilles Therapeutics plc (ACHL) stock when it goes public
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
-
How to buy SEMrush Holdings Inc (SEMR) stock when it goes public
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
-
How to buy ChargePoint (SYNH.US) stock when it goes public
Everything we know about the ChargePoint IPO, plus information on how to buy in.
-
How to buy Kaltura Inc (KLTR) stock when it goes public
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
-
How to buy Rocket Lab (SYNH.US) stock when it goes public
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
-
How to buy Soho House (SYNH.US) stock when it goes public
Everything we know about the Soho House IPO, plus information on how to buy in.
-
How to buy VIZIO (VZIO) stock when it goes public
Everything we know about the VIZIO IPO, plus information on how to buy in.
-
How to buy IDW Media Holdings Inc (IDW) stock when it goes public
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
-
How to buy Karooooo Ltd (KARO) stock when it goes public
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
-
How to buy Connect Biopharma Holdings Limited (CNTB) stock when it goes public
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
Ask an Expert